Literature

Drug-Eluting Beads on thyroid cancer metastasis: early experience of an oncological center (workshop)

Where presented 27 - 30 April 2011, Paris, France
Conference Global Embolization Symposium and Technologies (GEST)
Author(s) A Manca
Resources

Download file

Prospective, phase II study of chemoemboization with drug-eluting beads for hepatic neuroendocrine metastases: interim analysis

Date 2 - 6 October 2010, Valencia, Spain
Where presented Cardiovascular and Interventional Radiological Society of Europe (CIRS)
Author(s) D. Reyes, I. Kamel, K. Hong et al.
Resources

Download file

Prospective Phase II Study of Chemoembolization with Drug-eluting Beads for Hepatic Neuroendocrine Metastases: Interim Analysis

Date 2 - 5 October 2010, Valencia Spain
Where presented Cardiovascular and Interventional Radiological Society of Europe (CIRSE)
Author(s) Prof J-F Geschwind
Resources

Download file

First report of a pilot study of trans arterial chemo-embolization (TACE) with drug eluting beads irinotecan (IRI) preloaded (DEBI) for liver metastases (LM) from uveal melanoma (UM)

Date 19 – 23 September 2009, Lisbon Portugal
Where presented Cardiovascular and Interventional Radiological Society of Europe (CIRSE)
Author(s) C. Aliberti, G. Benea, M. Tilli, et al
Resources

Download file

Toxicity of irinotecan eluting beads in the treatment of hepatic malignancies: results of multi-institutional registry

Date 19 – 23 September 2009, Lisbon Portugal
Where presented Cardiovascular and Interventional Radiological Society of Europe (CIRSE)
Author(s) R.C.G. Martin, J. Howard, D. Tomalty, et al
Resources

Download file

Toxicity of Irinotecan Eluting Beads in the treatment of Hepatic Malignancies: Results of Multi-Institutional Registry. R.C.G. Martin

Date 19 – 23 September 2009, Lisbon Portugal
Where presented Cardiovascular and Interventional Radiological Society of Europe (CIRSE)
Author(s) 1, J. Howard2, D. Tomalty3, K. Robbins4, R. Padr5, P.M. Bosnjakovic6; 1Surgery, Division of Surgical Oncology, University of Louisville, Louisville, KY, United States, 2North Mississippi Medical Center, Tupelo, MS, United States, 3Huntsville Hospital, Huntsville, AL, United States, 4Baptist Health, Little Rock, AR, United States, 5FN v Motole, Motole, Czech Republic, 6Centar Nis Serbia, Nis, Serbia.
Resources

Download file

Chemoembolization (TACE) of Unresectable Intrahepatic Cholangiocarcinoma with Slow-Release Doxorubicin-Eluting Beads

Date 22 - 25 June 2008, Los Angeles, California
Where presented WCIO 2008 & Best of ASCO
Author(s) C Aliberti, G Benea, M Tilli et al
Resources

Download file

Drug-Eluting Beads: Future Product Applications

Date 12 June 2008, Kuala Lumpur, Malaysia
Where presented APCCVIR
Author(s) Dr Eva Gallardo
Resources

Download file

Drug-Eluting Beads: Clinical Updates and Histological Data

Date 12 June 2008, Kuala Lumpur, Malaysia
Where presented APCCVIR
Author(s) Dr Eva Gallardo
Resources

Download file

Drug-Eluting Beads: Advanced Applications (Colorectal Metastases, Neuroendocrine Metastases and Combination with RFA)

Date 12 June 2008, Kuala Lumpur, Malaysia
Where presented APCCVIR
Author(s) Dr Eva Gallardo
Resources

Download file

Product Assessment and Expanded Opportunities in Embolotherapy

Date 7 June 2008, Barcelona, Spain
Where presented GEST 2008 Satellite Symposium
Author(s) Dr Thierry De Baere, Institut de Cancerologie Gustave Roussy, Villejuif, France
Resources

Download file

Evaluation of Irinotecan Drug Eluting Beads: A new Drug Device Combination product for the chemoembolisation of Hepatic Metastases

Date 2006
Where presented 9th European Symposium on Controlled Drug Delivery
Author(s) Tang Y
Resources

Download file

Regulatory notices and product safety data

Worldwide (excluding USA and Canada)

DC Bead® is CE marked and is indicated for the treatment of malignant hypervascular tumours and loading with doxorubicin drug. DC Bead® is also indicated for loading with irinotecan for the treatment of metastatic colorectal cancer (mCRC). For full prescribing information please refer to DC Bead instructions for use.

USA

DC Bead is not currently available for sale or distribution in the USA. DC Bead has not been submitted for approval to the FDA.

Canada

DC Bead® with doxorubicin is indicated for trans-arterial chemoembolization (TACE) of unresectable hepatocellular carcinoma (HCC). DC Bead are also intended to be loaded with irinotecan for the purpose of embolization of vessels supplying malignant colorectal cancer metastasised to the liver (mCRC), and delivery of a local, controlled, sustained dose of irinotecan to the mCRC. For full prescribing information please refer to DC Bead Canada Instructions for Use 

Tawain

DC Bead is approved by the Department of Health and is intended to be loaded with Mayne (Hospira) doxorubicin HCI for the purpose of embolisation of vessels supplying malignant hypervascularised tumour(s), and delivery of a local, controlled, sustained dose of doxorubicin.  DC Bead is also indicated for the embolisation of nidus vessels without medication.  Approved size ranges in Taiwan are 300-500µm and 500-700µm.